[go: up one dir, main page]

JO3060B1 - تركيبه صيدلانيه لعامل مضاد لمستقبل التاكي كينين - Google Patents

تركيبه صيدلانيه لعامل مضاد لمستقبل التاكي كينين

Info

Publication number
JO3060B1
JO3060B1 JOP/2002/0126A JOP20020126A JO3060B1 JO 3060 B1 JO3060 B1 JO 3060B1 JO P20020126 A JOP20020126 A JO P20020126A JO 3060 B1 JO3060 B1 JO 3060B1
Authority
JO
Jordan
Prior art keywords
phenyl
pharmaceutical compositions
receptor antagonist
techykinin
pharmaceutical composition
Prior art date
Application number
JOP/2002/0126A
Other languages
English (en)
Inventor
William Bosch H
Liversidge Elaine
D SHELUKAR Suhas
C Thompson Karen
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23331619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3060(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of JO3060B1 publication Critical patent/JO3060B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات صيدلانية جديدة من المركب 2- (R) –(1 - (R) –(3- 5 بس( تراي فلورو ميثيل) فينيل) ايثوكسي) -3-( S) (4- فلورور) فينيل -4- ( 3-5 اوكسو – 1H ، 4H ، 1-، 2، 4 – تراي ازولو) ميثيل مورفولين، والتركيبات الصيدلانية لهذا الاختراع مفيدة في علاج، او الوقاية من الاضطرابات النفسية بما فيها الاكتئاب والقلق، والامراض الالتهابية والقيء.
JOP/2002/0126A 2001-12-10 2002-12-03 تركيبه صيدلانيه لعامل مضاد لمستقبل التاكي كينين JO3060B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34004001P 2001-12-10 2001-12-10

Publications (1)

Publication Number Publication Date
JO3060B1 true JO3060B1 (ar) 2017-03-15

Family

ID=23331619

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2002/0126A JO3060B1 (ar) 2001-12-10 2002-12-03 تركيبه صيدلانيه لعامل مضاد لمستقبل التاكي كينين

Country Status (38)

Country Link
US (1) US8258132B2 (ar)
EP (1) EP1455756B2 (ar)
JP (1) JP4532114B2 (ar)
KR (1) KR20040063991A (ar)
CN (1) CN100352443C (ar)
AR (1) AR037713A1 (ar)
AT (1) ATE400254T1 (ar)
AU (1) AU2002360824B8 (ar)
BR (1) BRPI0214786B8 (ar)
CA (1) CA2469315C (ar)
CO (1) CO5590887A2 (ar)
CY (1) CY1108354T1 (ar)
DE (1) DE60227556D1 (ar)
DK (1) DK1455756T4 (ar)
DO (1) DOP2002000542A (ar)
EA (1) EA007332B1 (ar)
EC (1) ECSP045144A (ar)
ES (1) ES2307820T5 (ar)
GE (1) GEP20063875B (ar)
HR (1) HRP20040532B1 (ar)
HU (1) HU230736B1 (ar)
IL (3) IL162296A0 (ar)
IS (1) IS2991B (ar)
JO (1) JO3060B1 (ar)
ME (1) ME00450B (ar)
MX (1) MXPA04005563A (ar)
MY (1) MY155911A (ar)
NO (1) NO336943B1 (ar)
NZ (1) NZ534009A (ar)
PE (1) PE20030641A1 (ar)
PL (1) PL211243B6 (ar)
PT (1) PT1455756E (ar)
RS (1) RS52280B (ar)
SI (1) SI1455756T2 (ar)
TW (1) TWI249403B (ar)
UA (1) UA76810C2 (ar)
WO (1) WO2003049718A1 (ar)
ZA (1) ZA200404012B (ar)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4482925B2 (ja) * 2002-02-22 2010-06-16 味の素株式会社 アミノ酸類粉末及びその製造方法
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
MX2007009915A (es) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
CA2617211A1 (en) * 2005-07-29 2007-02-08 Dr. Reddy's Laboratories Ltd. Amorphous aprepitant coprecipitates
EP1959966B1 (en) * 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
EP1984359A1 (en) 2006-02-03 2008-10-29 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
WO2007147160A2 (en) * 2006-06-16 2007-12-21 Dr. Reddy's Laboratories Ltd. Aprepitant compositions
WO2008026216A2 (en) * 2006-08-28 2008-03-06 Hetero Drugs Limited Process for purification of aprepitant
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
EP1970057A1 (en) * 2007-03-13 2008-09-17 Sandoz AG Process for the preparation of stable pharmaceutical compositions of 2-(R) - (1-(R)-(3, 5- bis (trifluoromethyl) phenyl) ethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-(5-oxo-1H, 4H-1, 2, 4-triazolo) methylmorpholine (aprepitant)
US20100151035A1 (en) * 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
US20110009362A1 (en) * 2008-02-27 2011-01-13 Dr. Reddy's Laboratories Ltd. Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
WO2009116081A2 (en) * 2008-03-03 2009-09-24 Msn Laboratories Limited An improved process for the preparation of aprepitant
EA201170913A1 (ru) * 2008-12-30 2012-01-30 Абды Ибрахым Иладж Санайи Ве Тыджарет Аноным Сыркеты Фармацевтические составы олмесартана
WO2010132634A1 (en) * 2009-05-15 2010-11-18 Glaxosmithkline Llc Using thermal imaging for control of a manufacturing process
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
US9040091B2 (en) * 2012-03-22 2015-05-26 Nanotherapeutics, Inc. Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
HK1221161A1 (zh) 2013-06-20 2017-05-26 Glenmark Pharmaceuticals S.A. 包含trpa1拮抗剂的纳米颗粒制剂
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
CN104367551B (zh) * 2013-08-15 2017-06-13 上海星泰医药科技有限公司 一种阿瑞匹坦复合物及其制备方法
JP2016532660A (ja) * 2013-10-08 2016-10-20 イノファーマ インク アプレピタント経口液体製剤
EP2893919B1 (en) 2014-01-09 2017-07-12 Sanofi Formulation of aprepitant with enhanced solubility
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
WO2016016861A1 (en) 2014-08-01 2016-02-04 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a mpges-1 inhibitor
KR101492572B1 (ko) 2015-01-14 2015-02-11 주식회사 대웅제약 신규 약학 조성물
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
GR1009002B (el) * 2016-03-22 2017-03-31 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
GR1009209B (el) * 2016-11-17 2018-02-05 Φαρματεν Αβεε Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου
CN106377517A (zh) * 2016-11-25 2017-02-08 遵义医学院 银杏内酯‑pvp纳米粒及其制备方法
CN107260705A (zh) * 2017-06-08 2017-10-20 武汉励合生物医药科技有限公司 一种阿瑞匹坦纳米胶囊的制备方法
US10792249B2 (en) 2017-07-24 2020-10-06 Acryspharm Llc High drug loading pharmaceutical compositions
JP2019073445A (ja) * 2017-10-12 2019-05-16 日本化薬株式会社 アプレピタントを有効成分とする医薬組成物
CN108066745A (zh) * 2017-12-26 2018-05-25 兆科药业（广州）有限公司 一种环孢素眼凝胶的处理工艺
WO2019162755A1 (en) 2018-02-20 2019-08-29 Ftf Pharma Private Limited Liquid compositions of aprepitant
WO2019191391A1 (en) * 2018-03-28 2019-10-03 The Regents Of The University Of Colorado, A Body Corporate Treatment and prevention of alpha herpes virus infection
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN110478316A (zh) * 2019-02-27 2019-11-22 江西中医药大学 一种阿瑞吡坦纳米结晶混悬剂及其制备方法和应用
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
EP3915546A1 (de) 2020-05-25 2021-12-01 Leon-Nanodrugs GmbH Verwendung von säure als lösungsmittel für präzipitationen
CN116077462B (zh) * 2022-12-01 2025-05-16 北京诺康达医药科技股份有限公司 阿瑞匹坦微丸及其制备方法和包含它的制剂
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096742A (en) 1990-01-09 1992-03-17 Hoechst Celanese Corporation High temperature, high humidity stabilization process for optical information storage media containing polycarbonate substrates
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5719147A (en) † 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) * 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
AU714542B2 (en) * 1996-06-26 2000-01-06 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
ZA985765B (en) † 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
GB9813025D0 (en) 1998-06-16 1998-08-12 Merck Sharp & Dohme Chemical synthesis
PT1107744E (pt) 1998-08-25 2003-08-29 Wolfgang Mueller Utilizacao de antagonistas da substancia p para o tratamento do sindrome de fadiga cronica e/ou fibromialgia
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6267989B1 (en) † 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2000076948A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. Process for the synthesis of 1-(3,5-bis(trifluoromethyl)-phenyl)ethan-1-one
US6255545B1 (en) 1999-06-11 2001-07-03 Merck & Co., Inc. Process for the synthesis of 3,5-bis(trifluoromethyl)-bromobenzene
US20070179367A1 (en) * 2000-05-02 2007-08-02 Ruchti Timothy L Method and Apparatus for Noninvasively Estimating a Property of an Animal Body Analyte from Spectral Data
US7801591B1 (en) * 2000-05-30 2010-09-21 Vladimir Shusterman Digital healthcare information management
WO2001094323A1 (en) 2000-06-08 2001-12-13 Merck & Co., Inc. Process for the synthesis of (2r, 2-alpha-r)-4-benzyl-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-1,4-oxazin-3-one
US8060173B2 (en) * 2003-08-01 2011-11-15 Dexcom, Inc. System and methods for processing analyte sensor data

Also Published As

Publication number Publication date
DOP2002000542A (es) 2003-07-15
ES2307820T3 (es) 2008-12-01
AU2002360824B2 (en) 2008-05-08
CY1108354T1 (el) 2012-05-23
CN1617712A (zh) 2005-05-18
NZ534009A (en) 2006-03-31
WO2003049718A1 (en) 2003-06-19
IS2991B (is) 2017-12-15
RS50404A (sr) 2007-04-10
EP1455756A1 (en) 2004-09-15
CA2469315C (en) 2008-12-02
CA2469315A1 (en) 2003-06-19
UA76810C2 (uk) 2006-09-15
DK1455756T3 (da) 2008-11-17
PL211243B1 (pl) 2012-04-30
EA200400794A1 (ru) 2004-10-28
HRP20040532B1 (en) 2012-09-30
NO336943B1 (no) 2015-11-30
BRPI0214786B1 (pt) 2018-11-27
IS7276A (is) 2004-05-21
JP2005516003A (ja) 2005-06-02
US20040214746A1 (en) 2004-10-28
MXPA04005563A (es) 2004-12-06
CN100352443C (zh) 2007-12-05
AR037713A1 (es) 2004-12-01
EP1455756B1 (en) 2008-07-09
RS52280B (sr) 2012-10-31
IL162296A (en) 2013-11-28
NO20042905L (no) 2004-09-10
TWI249403B (en) 2006-02-21
BRPI0214786B8 (pt) 2021-05-25
PT1455756E (pt) 2008-10-16
GEP20063875B (en) 2006-07-10
ME00450B (me) 2011-10-10
ZA200404012B (en) 2005-10-26
BR0214786A (pt) 2004-11-09
AU2002360824A1 (en) 2003-06-23
CO5590887A2 (es) 2005-12-30
MY155911A (en) 2015-12-15
ES2307820T5 (es) 2016-01-13
DE60227556D1 (de) 2008-08-21
ECSP045144A (es) 2004-07-23
HU230736B1 (hu) 2018-01-29
KR20040063991A (ko) 2004-07-15
ATE400254T1 (de) 2008-07-15
PE20030641A1 (es) 2003-07-23
HRP20040532A2 (en) 2004-10-31
DK1455756T4 (en) 2016-01-04
AU2002360824B8 (en) 2008-05-22
JP4532114B2 (ja) 2010-08-25
PL211243B6 (pl) 2023-01-23
HK1078017A1 (zh) 2006-03-03
SI1455756T1 (sl) 2008-12-31
US8258132B2 (en) 2012-09-04
IL201658A0 (en) 2011-08-01
EA007332B1 (ru) 2006-08-25
SI1455756T2 (sl) 2016-01-29
PL369887A1 (en) 2005-05-02
HUP0402596A3 (en) 2011-05-30
HUP0402596A2 (hu) 2005-03-29
IL162296A0 (en) 2005-11-20
EP1455756B2 (en) 2015-09-23
TW200301125A (en) 2003-07-01

Similar Documents

Publication Publication Date Title
JO3060B1 (ar) تركيبه صيدلانيه لعامل مضاد لمستقبل التاكي كينين
ZA985765B (en) Polymorphic form of a tachykinin receptor antagonist.
IS2617B (is) Fjölbrigðaform af kínínhröðunar mótlyfinu 2-(R)-(1-(R)-(3,5-bis(tríflúormetýl)fenýl)etoxý)-3-(S)-(4-flúor)fenýl-4-(3-(5-oxó-1H,4H-1,2,4-tríasóló)metýlmorfólíni
EP1423111A4 (en) FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
HU9401543D0 (en) Aryl-substituted heterocycles
CA2408934A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
MY140835A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
UA84399C2 (en) Process for the preparation of 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one
WO2002034699A3 (en) Mammalian metabolites of a tachykinin receptor antagonist
AR026288A1 (es) Forma polimorfica de un antagonista del receptor de taquicinina
MY126509A (en) Polymorphic form of a tachykinin receptor antagonist
TH72742B (th) องค์ประกอบทางเภสัชกรรมของสารต้านตัวรับแทคคีไคนิน
TH47996A (th) รูปแบบโพลีมอร์ฟิกของยาต้านฤทธิ์ตัวรับของแทกกีคินิน
TH17690B (th) รูปแบบโพลีมอร์ฟิกของยาต้านฤทธิ์ตัวรับของแทกกีคินิน
ECSP003740A (es) Forma polimorfica de un antagonista de receptor de taquiquinina